Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

被引：0
|
作者：
Leonie JM Mekenkamp
Jolien Tol
Jeroen R Dijkstra
Inge de Krijger
M Elisa Vink-Börger
Shannon van Vliet
Steven Teerenstra
Eveline Kamping
Eugène Verwiel
Miriam Koopman
Gerrit A Meijer
J Han JM van Krieken
Roland Kuiper
Cornelis JA Punt
Iris D Nagtegaal
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology
[2] Radboud University Nijmegen Medical Centre,Department of Pathology
[3] Radboud University Nijmegen Medical Centre,Department of Epidemiology, Biostatistics and Health Technology Assessment
[4] Radboud University Nijmegen Medical Centre,Department of Human Genetics
[5] University Medical Center Utrecht,Department of Medical Oncology
[6] VU University Medical Center,Department of Pathology
[7] University of Amsterdam,Department of Medical Oncology, Academic Medical Centre
来源：
BMC Cancer | / 12卷
关键词：
Cetuximab; KRAS Mutation; Copy Number Change; Poor Responder; Copy Number Gain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
    Modest, Dominik P.
    Stintzing, Sebastian
    Laubender, Ruediger P.
    Neumann, Jens
    Jung, Andreas
    Giessen, Clemens
    Haas, Michael
    Aubele, Philipp
    Schulz, Christoph
    Boeck, Stefan
    Stemmler, Hans-Joachim
    Kirchner, Thomas
    Heinemann, Volker
    ANTI-CANCER DRUGS, 2011, 22 (09) : 913 - 918
  • [2] Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients
    Zavodna, K.
    Konecny, M.
    Krivulcik, T.
    Spanik, S.
    Behulova, R.
    Vizvaryova, M.
    Weismanova, E.
    Galbavy, S.
    Kausitz, J.
    NEOPLASMA, 2009, 56 (03) : 275 - 278
  • [3] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Fortunato Ciardiello
    Sabine Tejpar
    Demetris Papamichael
    Targeted Oncology, 2009, 4 : 311 - 322
  • [4] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Ciardiello, Fortunato
    Tejpar, Sabine
    Papamichael, Demetris
    TARGETED ONCOLOGY, 2009, 4 (04) : 311 - 322
  • [5] Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
    Fornaro, Lorenzo
    Baldi, Giacomo Giulio
    Masi, Gianluca
    Allegrini, Giacomo
    Loupakis, Fotios
    Vasile, Enrico
    Cupini, Samanta
    Stasi, Irene
    Salvatore, Lisa
    Cremolini, Chiara
    Vincenzi, Bruno
    Santini, Daniele
    Tonini, Giuseppe
    Graziano, Francesco
    Ruzzo, Annamaria
    Canestrari, Emanuele
    Magnani, Mauro
    Falcone, Alfredo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (03) : 243 - 251
  • [6] Influence of KRAS Mutation Status in Metachronous and Synchronous Metastatic Colorectal Adenocarcinoma
    Rose, Jeffrey S.
    Serna, Derek S.
    Martin, Ludmila Katherine
    Li, Xiaobai
    Weatherby, Lynn M.
    Abdel-Misih, Sherif
    Zhao, Weiqiang
    Bekaii-Saab, Tanios
    CANCER, 2012, 118 (24) : 6243 - 6252
  • [7] Impact of KRAS Mutation on Outcome of Patients with Metastatic Colorectal Cancer
    Chang, Yu-Yao
    Lin, Jen-Kou
    Lin, Tzu-Chen
    Chen, Wei-Shone
    Jiang, Jeng-Kai
    Yang, Shung-Haur
    Wang, Huann-Sheng
    Lan, Yuan-Tzu
    Lin, Chun-Chi
    Liang, Wen-Yih
    Chang, Shih-Ching
    HEPATO-GASTROENTEROLOGY, 2014, 61 (135) : 1946 - 1953
  • [8] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [9] The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011
    Lievre, A.
    Artru, P.
    Guiu, M.
    Laurent-Puig, P.
    Merlin, J. L.
    Sabourin, J. C.
    Viguier, J.
    Bastie, A.
    Seronde, A.
    Ducreux, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2126 - 2133
  • [10] Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
    Kim, Mi-Jung
    Lee, Hye Seung
    Kim, Jee Hyun
    Kim, Yu Jung
    Kwon, Ji Hyun
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Park, Kyoung Un
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Jae-Sung
    Lee, Jong Seok
    Lee, Keun-Wook
    BMC CANCER, 2012, 12
12345